292 related articles for article (PubMed ID: 30577702)
1. Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures.
de Biase S; Gigli GL; Nilo A; Romano G; Valente M
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):93-102. PubMed ID: 30577702
[TBL] [Abstract][Full Text] [Related]
2. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
[No Abstract] [Full Text] [Related]
3. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Gidal BE; Ferry J; Majid O; Hussein Z
Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
[TBL] [Abstract][Full Text] [Related]
4. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation.
Schulze-Bonhage A
Expert Opin Drug Metab Toxicol; 2015; 11(8):1329-37. PubMed ID: 26111428
[TBL] [Abstract][Full Text] [Related]
5. Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy.
Faulkner MA
Drug Des Devel Ther; 2017; 11():2921-2930. PubMed ID: 29042752
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures.
Takenaka O; Ferry J; Saeki K; Laurenza A
Acta Neurol Scand; 2018 Apr; 137(4):400-408. PubMed ID: 29171002
[TBL] [Abstract][Full Text] [Related]
7. Perampanel: A Review in Drug-Resistant Epilepsy.
Frampton JE
Drugs; 2015 Sep; 75(14):1657-68. PubMed ID: 26370209
[TBL] [Abstract][Full Text] [Related]
8. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
[TBL] [Abstract][Full Text] [Related]
9. Timing use of novel anti-epileptic drugs: is earlier better?
de Biase S; Nilo A; Bernardini A; Gigli GL; Valente M; Merlino G
Expert Rev Neurother; 2019 Oct; 19(10):945-954. PubMed ID: 31257949
[No Abstract] [Full Text] [Related]
10. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
[TBL] [Abstract][Full Text] [Related]
11. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy.
Rohracher A; Brigo F; Höfler J; Kalss G; Neuray C; Dobesberger J; Kuchukhidze G; Leitinger M; Trinka E
Expert Opin Pharmacother; 2016 Jul; 17(10):1403-11. PubMed ID: 27267634
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
[TBL] [Abstract][Full Text] [Related]
13. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
[TBL] [Abstract][Full Text] [Related]
14. Budget impact of perampanel as adjunctive treatment of uncontrolled partial-onset and primary generalized tonic-clonic seizures in the United States.
Tremblay G; Barghout V; Patel V; Tsong W; Wang Z
Epilepsy Behav; 2017 Mar; 68():196-202. PubMed ID: 28236697
[TBL] [Abstract][Full Text] [Related]
15. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
[TBL] [Abstract][Full Text] [Related]
16. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
[TBL] [Abstract][Full Text] [Related]
19. Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures.
Franco V; Iudice A; Grillo E; Citraro R; De Sarro G; Russo E
Expert Opin Pharmacother; 2014 Apr; 15(5):637-44. PubMed ID: 24437529
[TBL] [Abstract][Full Text] [Related]
20. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
